Afya (NASDAQ:AFYA) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Posted by Stanley Muller on Aug 15th, 2026

Afya (NASDAQ:AFYA – Get Free Report) released its earnings results on Thursday. The company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.40 by $0.03, FiscalAI reports. The firm had revenue of $187.80 million for the quarter, compared to analyst estimates of $189.62 million. Afya had a net margin of 20.55% and a return on equity of 18.02%.

Here are the key takeaways from Afya’s conference call:

First-half revenue grew 7% to BRL 1.985 billion, while net income increased 7% to BRL 463 million and EPS rose 9% to BRL 5.10. Medical undergraduate revenue benefited from 3% student growth and a nearly 4% increase in average tuition.
Adjusted EBITDA margin contracted 190 basis points to 46.2%, mainly because of higher sales and marketing investments in continuing education and medical practice solutions. Management maintained its full-year EBITDA guidance of BRL 1.7–1.8 billion, implying a potentially slower second half versus the first.
Cash generation remained strong, with BRL 806 million in operating cash flow, BRL 423 million in first-half FCFE, and 87.8% cash conversion. Afya returned BRL 448 million to shareholders through dividends and buybacks, exceeding first-half FCFE, while net leverage remained low at 0.8x EBITDA.
Medical Practice Solutions revenue grew only 2% to BRL 85 million, and monthly active users declined 8% year over year. Management cited competitive pressure from AI tools affecting Whitebook payers, although clinical-management payers grew 20% and further product investment is intended to support future recovery.
Continuing education revenue rose 5% to BRL 144 million, but growth was constrained by a shift toward shorter-duration, lower-ticket programs and seasonal weakness. Management expects high-single-digit growth in the second half and said it remains on track to meet its 2026 guidance.

Afya Trading Up 3.2%

Shares of Afya stock traded up $0.43 during mid-day trading on Friday, hitting $13.84. The stock had a trading volume of 174,965 shares, compared to its average volume of 96,339. Afya has a 12-month low of $13.00 and a 12-month high of $16.50. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.42. The firm has a 50-day moving average of $14.26 and a two-hundred day moving average of $14.41. The firm has a market cap of $1.30 billion, a P/E ratio of 8.44, a price-to-earnings-growth ratio of 1.42 and a beta of 0.34.

Afya News Summary

Here are the key news stories impacting Afya this week:

Positive Sentiment: Profitability improved: Afya reported second-quarter revenue of $187.8 million, up 10.95% year over year, while net income rose 22.57% to $38.9 million. Diluted EPS increased to $0.43 from $0.40, and operating cash flow reached $64.3 million. Afya Second-Quarter and First-Half 2026 Financial Results
Positive Sentiment: EPS exceeded the broader consensus: The company’s $0.43 quarterly EPS surpassed the reported consensus estimate of $0.40, while Afya maintained a healthy 20.2% net margin and 17.94% return on equity. Afya Earnings Results
Positive Sentiment: Cost and balance-sheet trends were supportive: Capital spending declined year over year, cash and equivalents totaled $194.4 million, and total liabilities were broadly unchanged. These factors may reinforce the investment case at a valuation of roughly 9 times earnings.
Neutral Sentiment: Results were mixed depending on the benchmark: Zacks reported adjusted quarterly EPS of $0.45, slightly below its $0.46 consensus estimate, while revenue also lagged some expectations. Afya Q2 Earnings and Revenues
Negative Sentiment: Fiscal 2026 revenue guidance was below expectations: Afya projected revenue of $750.2 million to $778.7 million, below the $781.6 million consensus estimate. EPS guidance was not provided in the supplied update, increasing uncertainty around the full-year outlook.
Negative Sentiment: Insider and institutional selling may weigh on sentiment: Recent data showed 19 insider sales and no insider purchases over six months, while more institutional investors reduced positions than added them. Afya Q2 Earnings and Institutional Activity

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on AFYA. Zacks Research lowered shares of Afya from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 6th. JPMorgan Chase & Co. lowered their price target on Afya from $21.50 to $21.00 and set a “neutral” rating on the stock in a research report on Monday, June 22nd. Wall Street Zen cut shares of Afya from a “buy” rating to a “hold” rating in a research report on Saturday. Weiss Ratings cut shares of Afya from a “hold (c)” rating to a “hold (c-)” rating in a research report on Friday, July 31st. Finally, Bank of America reissued a “neutral” rating on shares of Afya in a report on Thursday, June 11th. Six investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $18.00.

Read Our Latest Stock Report on Afya

Insider Buying and Selling

In other news, VP Gomiero Mirella Basolli sold 10,000 shares of the stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $14.80, for a total transaction of $148,000.00. Following the transaction, the vice president owned 34,530 shares of the company’s stock, valued at approximately $511,044. This trade represents a 22.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Lelio De Souza Junior sold 36,204 shares of Afya stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $15.00, for a total value of $543,060.00. The SEC filing for this sale provides additional information. Insiders have sold a total of 87,745 shares of company stock valued at $1,314,175 over the last ninety days. 0.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Afya

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Susquehanna International Group LLP acquired a new position in shares of Afya during the 3rd quarter worth about $419,000. BNP Paribas Financial Markets boosted its holdings in Afya by 175.2% during the second quarter. BNP Paribas Financial Markets now owns 25,511 shares of the company’s stock worth $456,000 after buying an additional 16,241 shares during the last quarter. Qube Research & Technologies Ltd acquired a new stake in shares of Afya during the third quarter worth about $610,000. Jump Financial LLC acquired a new position in shares of Afya during the second quarter worth about $731,000. Finally, Lazard Asset Management LLC grew its holdings in shares of Afya by 167.6% in the 3rd quarter. Lazard Asset Management LLC now owns 49,399 shares of the company’s stock valued at $771,000 after acquiring an additional 30,936 shares in the last quarter. Institutional investors own 88.02% of the company’s stock.

About Afya

(Get Free Report)

Afya Ltd. operates as a leading provider of medical education and training services in Brazil. The company offers a comprehensive suite of educational programs that span undergraduate medical degrees, residency exam preparation, continuing medical education (CME) and digital learning platforms. Through a network of partner institutions and its own campus operations, Afya supports students at every stage of the medical training continuum, from enrollment in medical schools to ongoing professional development for practicing physicians.

At the core of Afya’s offerings is its undergraduate medical program, delivered through a combination of in-person courses at affiliated campuses and fully digital curricula.